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ABSTRACT 
The ephrin receptor A4 (EphA4) is one of the 
receptors in the ephrin system that plays a 
pivotal role in a variety of cell-cell interactions, 
mostly studied during development. In addition, 
EphA4 has been found to play a role in cancer 
biology as well as in the pathogenesis of several 
neurological disorders such as stroke, spinal cord 
injury, multiple sclerosis (MS), amyotrophic 
lateral sclerosis (ALS) and Alzheimer’s disease 
(AD). Pharmacological blocking of EphA4 has 
been suggested to be a therapeutic strategy for 
these disorders. Therefore, the aim of our study 
was to generate potent and selective Nanobodies 
against the ligand-binding domain of the human 
EphA4 receptor. We identified two Nanobodies, 
Nb 39 and Nb 53, that bind EphA4 with 
affinities in the nanomolar range. These 
Nanobodies were most selective for EphA4, with 
residual binding to EphA7 only. Using 
Alphascreen technology, we found that both 
Nanobodies displaced all known EphA4-binding 
ephrins from the receptor. Furthermore, Nb 39 
and Nb 53 inhibited ephrin-induced 
phosphorylation of the EphA4 protein in a cell-
based assay. Finally, in a cortical neuron primary 
culture, both Nanobodies were able to inhibit 
endogenous EphA4-mediated growth cone 
collapse induced by ephrin-B3. Our results 
demonstrate the potential of Nanobodies to target 
the ligand-binding domain of EphA4. These 
Nanobodies may deserve further evaluation as 
potential therapeutics in disorders in which 
EphA4-mediated signalling plays a role.  
Ephrin receptors, the largest family of 
receptor tyrosine kinases, are subdivided in A- 
and B- class receptors. In mammals there are 
nine EphA receptors (EphA1-EphA8, EphA10) 
that interact with five ephrin-A ligands (ephrin-
A1- ephrin-A5) and five EphB receptors 
(EphB1-EphB4, EphB6) that interact with three 
ephrin-B ligands (ephrin-B1-ephrin-B3) (1). 
There is some interclass promiscuity as EphA4 
can also interact with ephrin-B ligands while 
EphB2 also interacts with ephrin-A5 (2-4).   
 The ephrin system plays a major role in a 
variety of cell-cell interactions. In the developing 
nervous system it is pivotal as an axonal 
guidance system, while in the adult brain, it is 
involved in synaptic plasticity and long-term 
potentiation (LTP) (5,6). Importantly, the ephrin 
system also plays a role in cancer biology and in 
the pathogenesis of several neurological 
disorders (5). EphA4 is upregulated in spinal 
cord injury, traumatic brain injury and stroke, 
and blocking of the receptor increases functional 
recovery in models for these conditions (7-9). 
Interestingly, antagonism of EphA4 improves 
LTP defects in a mouse model for Alzheimer’s 
Disease (AD) and improves outcome in animal 
models for Amyotrophic Lateral Sclerosis (ALS) 
and stroke (9-12). EphA4 expression is inversely 
correlated with survival time in ALS patients, 
which suggests that EphA4 is also involved in 
ALS human pathology (11). These findings 
suggest that EphA4 inhibition may have 
potential for the treatment of neurological 
disorders.  
 Inhibition of EphA4 signaling can be 
accomplished by targeting the ATP-binding 
pocket in the kinase domain or by blocking the 
interaction with ephrin ligands (13,14). Because 
the ATP-binding pocket is highly conserved 
among tyrosine kinases it is very difficult to 
develop selective inhibitors (13). Alternatively 
targeting the ligand-binding domain (LBD) 
certainly allows the development of more 
selective compounds, but this poses several other 
problems. On one hand, the protein interaction 
surface to be covered is large; 900 A² in the case 
of EphA4 (15,16). On the other hand, the LBD is 
dynamic by nature, as EphA4 can adopt a 
conformation similar to other EphA receptors 
upon interaction with ephrin-A ligands, or 
characteristics of EphB receptors when 
interacting with ephrin-B ligands (2,4,17).    
  Nevertheless several peptides and small 
molecules have been identified that bind the 
EphA4 LBD and block its interaction with ephrin 
ligands (18-22). One of these EphA4 antagonists 
is the KYL-peptide, which has been extensively 
characterised and shown to be effective in 
several in vitro assays as well as in in vivo spinal 
cord injury and ALS models (11,19,23,24), 
suggesting the potential of an EphA4-based 
therapeutic approach.  
  The aim of this study was to develop 
highly selective and potent EphA4 inhibitors. In 
order to achieve this goal, we took advantage of 
the Nanobody technology (25-27). Nanobodies 
(Nbs) or VHHs are small antigen-binding 
fragments derived from camelid heavy-chain 
only antibodies that are devoid of light chains. 
They are superior to conventional antibodies in 
terms of stability, solubility and immunogenicity 
(27). Furthermore, they are much smaller than 
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conventional antibodies (12-15 kDa versus 150-
160 kDa) and can penetrate small clefts and 
cavities (28).   
  We were able to generate Nbs against the 
LBD of the EphA4 receptor. Two of these Nbs 
specifically bind the EphA4 receptor with 
nanomolar affinities and block ephrin-induced 
EphA4 phosphorylation and EphA4-mediated 
actin remodelling in a growth cone collapse 
assay. These results demonstrate the potential of 
Nbs to selectively target the LBD of the EphA4 
receptor. These Nbs may be useful as a 
therapeutic strategy in disorders in which EphA4 
plays a pathogenic role. 
 
Results 
Generation of anti-EphA4 LBD Nbs 
An alpaca was immunized with recombinant 
human EphA4 LBD  according to standard 
procedures (29). In addition to conventional 
antibodies, alpacas also produce heavy-chain 
only antibodies in response to an immunogen. A 
phagemid library displaying Nbs was constructed 
from the RNA extracted from peripheral blood 
lymphocytes and transformed in E.coli TG1 
cells. A library of about 2 × 108 independent 
transformants was obtained and about 87% of 
transformants harboured the vector with the right 
insert size.  Phage particles were generated and 
subjected to panning. After four consecutive 
rounds of panning, we obtained 41 colonies that 
expressed antigen-specific Nbs in their 
periplasmic extracts, as determined by ELISA. 
Sequencing of the Nb genes from these 41 
positive colonies resulted in 15 different Nbs. 
Characteristically Nbs contain three 
complementary determining regions (CDRs), 
which contribute to antigen binding specificity.  
Based on sequence homology they belonged to 
nine different clonally-unrelated B-cell clones 
(Figure 1). Nbs belonging to the same group 
showed very high sequence similarity suggesting 
that they are originating from clonally-related B-
cells that underwent hypermutation. Nbs 39, 16, 
71, 28 and 22 most likely belong to unrelated B-
cell clones.   
 
Expression of the anti-EphA4 LBD Nbs  
Phagemids encoding the Nbs of interest were 
transformed into WK6 E.coli cells to allow 
expression of the Nbs without the pIII fusion. 
The expressed Nbs were recovered from the 
periplasmic extracts and purified. Their purity 
and was analysed by Coomassie-stained SDS-
polyacrylamide gels and their identity was 
determined with Western Blot detection using 
His6-tag (data not shown). All Nbs could be 
detected at a position corresponding to about 15 
kDa. However, there were obvious differences in 
expression levels of the Nbs (data not shown). 
Concentration of poorly expressed Nbs 90, 16, 
71, 28 and 10 resulted in protein aggregation. 
Therefore, we did not include these Nbs in 
further analyses.  
 
Analysis of EphA4 binding 
We next determined whether the Nbs recognised 
EphA4 under reducing, none-native conditions. 
None of them bound recombinant EphA4 (data 
not shown) on Western Blot. An EphA4 
monoclonal antibody was used as a positive 
control and readily bound the denatured 
recombinant protein. These data suggested that 
the Nbs target a conformational epitope on the 
EphA4 LBD. To test whether the Nbs were 
indeed able to bind native EphA4, we performed 
immunoprecipitation experiments (Figure 2). 
Nbs 31, 39, 50, 53 and 57 precipitated EphA4 
protein and EphA4 in turn precipitated these Nbs 
(data shown only for Nbs 53 and 39 in figure 2A, 
B). In contrast to the other Nbs, Nb 22 showed 
lower binding to mouse EphA4 compared to 
human EphA4 (Figure 2C). Nbs 19, 34 and 47 
revealed non-specific binding to the beads and to 
recombinant ephrin-B2 (data shown only for Nb 
19 and 47 in Figure 2D, E). Nb 60 did not show 
non-specific binding to the beads, but 
precipitated with recombinant ephrin-B2 
indicating cross-reactivity with ephrin-B2 
(Figure 2F).   
 
To identify the Nbs with the highest affinity, we 
determined their binding kinetics to EphA4 using 
Surface Plasmon Resonance (SPR). The EphA4 
LBD was immobilized onto the chip and Nbs (1 
nM to 300 nM) were used as analyte. SPR 
analyses revealed that Nbs 34 and 47 do not bind 
to the EphA4 LBD (Table 1). Nbs 22, 31, 39, 50, 
53, 57 and 60 bound in the low nanomolar range, 
while Nb 19 only interacted with EphA4 LBD in 
the higher nanomolar range (Table 1). 
We next investigated the affinity of the Nbs for 
full-length recombinant human and mouse 
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EphA4 receptor. Most Nbs showed similar 
binding to the full-length receptor as to the 
EphA4 LBD. Nb 22 showed a two-fold 
difference in binding affinity between human 
and mouse EphA4, in agreement with what we 
found in immunoprecipitation experiments 
(Figure 2C). 
Based on these results, we selected seven Nbs 
(60, 57, 39, 22, 31, 50 and 53) with affinities in 
the nanomolar range for both the EphA4 LBD 
and the full-length receptor.  
  
Cross-reactivity with other Eph receptors 
 
Since the homology between the different Eph 
receptors is very high, we used Alphascreen 
technology to study the specificity of the Nbs 
generated. All Eph receptors tested showed 
binding with ephrin-A5 and/or ephrin-B2 
indicating that all receptors adopted their correct 
conformation. Ephrin-A5 interacted with all 
EphA receptors and with EphB2 as has been 
previously shown (data not shown) (3). Ephrin-
B2 interacted with all EphB receptors and 
EphA4, but not with EphB6 for which no ligands 
have been identified so far (data not shown) 
(4,30). The control Nb did not bind to any of the 
Eph receptors as expected (data not shown). 
Alphascreen analyses showed that Nb 60 
interacted with several Eph receptors other than 
EphA4 (Figure 3A), in agreement with the 
immunoprecipitation results obtained with this 
Nb (Figure 2F). Nb 57 bound EphA4, but also 
EphA3 and EphA7, and Nb 50 bound EphA4 but 
also EphA3, EphA6, EphA7 and EphA8 (Figure 
3B,F). Nbs 22, 31, 39 and 53 were almost 
completely selective for EphA4, although some 
binding to EphA7 was detected (Figure 3C, D, E, 
G). We therefore selected the latter four for 
further screening.  
 
Competition with ephrin ligands for the 
interaction with EphA4    
  
EphA4 interacts with most of the ephrins (2,4). 
We therefore investigated whether the selected 
Nbs were able to displace the ligands from the 
EphA4 receptor. We determined the optimal 
concentration for the different ephrin ligands 
using a fixed concentration of the EphA4 LBD to 
avoid the hooking effect and we added 
increasing concentrations of the Nbs. The control 
Nb did not compete with any ephrin ligand for 
the interaction with EphA4, as expected (data not 
shown). The KYL peptide, a known EphA4 
inhibitor, was used as a positive control. 
Nb 39 and Nb 53 completely displaced all ephrin 
ligands from EphA4 binding in a concentration 
range lower than the KYL-peptide (Figure 4A-
H). Nbs 22 and 31 were less potent. Nb 22 
completely displaced ephrin-A3 (Figure 4C) and 
almost completely displaced ephrin-B ligands 
(Figure 4F, G, H) from EphA4 binding, but no 
full displacement of the other ephrin-A ligands 
was obtained with the concentrations tested 
(Figure 4A, B, D, E). Its potency was 
comparable to that of the KYL peptide.  Nb 31 
completely displaced ephrin-A1, ephrin-B1 and 
ephrin-B2 at lower concentrations than the KYL-
peptide (Figure 4A, F, G), and completely 
displaced ephrin-A3 with concentrations similar 
to the KYL-peptide (Figure 4C). However, 
ephrin-A2, ephrin-A4, ephrin-A5 and ephrin-B3 
could not be completely displaced with the 
concentrations tested (Figure 4B, D, E). These 
data show that Nbs 39 and 53 were able to block 
the interaction of all ephrin ligands with the 
EphA4 LBD.  
To examine the potency of Nb 39 and 53, in 
inhibiting another Eph receptor, EphA7, 
compared to EphA4, we determined the capacity 
of these two Nbs to modify the interaction 
between EphA7 and ephrin-A5 in a competition 
assay. We determined the optimal binding 
concentrations of EphA7 and ephrin-A5. At a 
concentration in which Nb 39 and Nb 53 were 
able to inhibit binding of ephrin-A5 to EphA4 
(Figure 4E) only partial inhibition of the 
interaction between EphA7 and ephrin-A5 could 
be detected (Figure 5). A control Nb did not 
compete with ephrin-A5-binding to EphA7 (data 
not shown). 
Inhibition of ephrin-induced EphA4 activation 
 
To assess the antagonistic properties of the Nbs, 
we tested their effect on ephrin-induced EphA4 
phosphorylation (31). Upon ephrin binding, Eph 
receptors are dimerised and activated by 
autophosphorylation (phosphorylation of 
tyrosine residues in the kinase domain and 
juxtamambrane region) (31). After clustering, the 
phosphorylated tyrosine residues form binding 
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sites for cytoplasmic targets with Src Homology 
2 (SH2) or Phosphotyrosine Binding (PTB) 
domains (31,32). In general, EphA4 
phosphorylation results in cell-cell segregation in 
this way regulating cytoskeleton dynamics and 
morphology (1). Ephrin-induced phosphorylation 
was examined using the PathHunter assay in 
U2OS cells. Cells were stimulated with ephrin-
A1 with or without the presence of an EphA4 
antagonist, and the resulting EphA4 
phosphorylation was measured. The control Nb 
did not have any effect on receptor 
phosphorylation (data not shown). The KYL-
peptide achieved complete inhibition of ephrin-
A1-induced phosphorylation with an IC50 value 
of 53 µM (Figure 6). Nbs 39 and 53 also 
completely inhibited ephrin-A1-induced 
phosphorylation, at lower concentrations than the 
KYL-peptide, with an IC50 of 170 nM and 261 
nM respectively (Figure 6). These data indicate 
that Nbs 39 and 53 are 200 to 300 times more 
potent than the KYL-peptide in inhibiting 
ephrin-A1-induced phosphorylation of the 
EphA4 receptor. 
 
Inhibition of ephrin-induced growth cone 
collapse 
A common cellular response downstream of Eph 
receptor activation is actin cytoskeleton 
reorganization, leading to cell morphology 
changes (1,33). Ephrin-B3 treatment of cortical 
neurons in vitro induces collapse of growth 
cones at the tip of the neurites, by reorganization 
of actin filaments (34,35). Cortical neurons 
lacking functional EphA4 show insensitivity to 
the ephrin-B3-mediated growth cone collapse, 
suggesting that this effect is EphA4-mediated 
(36). We next determined whether the Nbs are 
also able to antagonize a cellular response such 
as growth cone collapse induced by an EphA4 
receptor agonist. To this end, we investigated 
their effect on the ephrin-B3 induced inhibition 
of neurite elongation in E17.5 embryonic cortical 
neurons. As described before, stimulation with 
preclustured recombinant ephrin-B3-Fc resulted 
in growth cone collapse as compared to an 
unstimulated condition and a condition 
stimulated with Fc only (Figure 7). As expected, 
KYL peptide antagonized this effect on growth 
cone collapse. Nb 53 as well as Nb 39 also 
inhibited the growth cone collapse effect 
mediated by ephrin-B3-Fc, at the concentration 
of 1 µM, a concentration at which the KYL 
peptide was ineffective (Figure 7).  
 
Nb stability in plasma 
We incubated Nb 39 and Nb 53 in heparinized 
mouse plasma at 37°C for up to 168h (7 days) to 
study the stability in plasma and obtained 
aliquots at different time-points. We determined 
the stability of Nbs with Western Blot using an 
anti-HA antibody. Some cleavage products could 
be observed from 24 hours onwards for both Nb 
39 and 53 (Figure 8A). Whereas full-length Nb 
39 remained stable across the timecourse, full-
length Nb 53 levels diminished with time from 
72 hours onwards, suggesting that Nb 53 is more 
prone to degradation in plasma than Nb 39 
(Figure 8A, B). No degradation products were 
detected for any of the Nbs after incubation in 
PBS at 37°C for the same time-course length 
(Figure 8C). In addition we studied if the binding 
capacity of Nbs to EphA4 was altered after 
incubation in plasma by Alphascreen technology. 
After 72h of incubation in plasma at 37°C, Nbs 
were still capable of binding EphA4 LBD 
(Figure 8D). 
 
Discussion 
 
In view of EphA4’s role in normal physiology as 
well as in cancer and neurodegeneration, the 
generation of potent and selective antagonists 
against this receptor is of great interest. The 
EphA4 LBD may be a better target than its 
tyrosine kinase moiety, because of the difficulty 
to obtain selective Eph tyrosine kinase inhibitors, 
and because of the need for such molecules to 
enter the cell. Here we show for the first time the 
generation of single domain antibodies targeting 
the LBD of EphA4. 
Nbs are in many ways superior to small 
molecules when targeting the LBD of Eph 
receptor proteins, as high affinity binding of the 
LBD requires the coverage of the protein 
interaction surface (900 A² for EphA4) in order 
to block the interaction with EphA4 ligands. 
Both Nb 39 and Nb 53 were able to block the 
interaction of EphA4 with all ephrin ligands and 
to inhibit ephrin-induced phosphorylation of 
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EphA4 and growth cone collapse triggered by 
ephrin-B3 binding to endogenous EphA4.  
 In previous studies, Nbs were used to fix 
receptors in one conformation (28,37). As a 
consequence Nbs are an ideal probe to target 
dynamic structures such as the EphA4 LBD 
(2,4,17). Four different conformations have been 
reported for the EphA4 LBD: a conformation 
similar to other EphA receptors bound with 
ephrin-A ligands (2,38), a conformation similar 
to EphB receptors bound with ephrin-B ligands 
(2,4,15) and two unbound conformations when 
free in solution (17). Fixing the EphA4 LBD in a 
specific conformation might limit the 
accessibility for all or a specific class of ephrin 
ligands, thereby blocking the interaction of those 
ligands with the LBD.  
Nb 39 and Nb 53 were most selective for EphA4, 
but still showed residual binding to EphA7, 
suggesting that they target a region that is not 
highly conserved in all Eph receptors. However 
concentrations of Nb 39 and Nb 53 that strongly 
inhibit EphA4 binding of ephrin ligands, the 
interaction between EphA7 and ephrin-A5 was 
only partially reduced. Interestingly, EphA7 KO 
mice as well as rats treated with EphA7 antisense 
oligonucleotides showed enhanced recovery after 
Spinal Cord Injury (SCI) compared to control 
mice (39), similar to the effects described for 
EphA4 antagonists (24). Therefore, if some 
binding to EphA7 would occur in addition to 
EphA4, this could potentially be of benefit rather 
than detrimental. 
In the last years, extensive work has been 
performed aiming to develop EphA4 antagonists 
with high affinity, specificity and with good 
pharmacokinetic profiles (14). One EphA4 
inhibitor, the KYL-peptide, has been studied 
extensively in models of neurological disorders, 
such as acute injuries including spinal cord 
injury and stroke, and neurodegenerative 
disorders such as ALS and AD (10,11). 
Unfortunately, this peptide has a KD value of 
approximately 1 µM as determined with 
Isothermal Titration Calorimetry (ITC) and a 
very short half-life in serum (11 min in mouse 
serum) (19,24). Interestingly, a recent study 
reported the generation of highly selective 
EphA4 antagonists with higher potency, the 
cyclic peptide APY-derivatives, APY-d3 and 
APY-d4 (16,22). APY-d3 and APY-d4 have KD 
values of 30 nM and 20 nM as determined with 
ITC, and inhibit ephrin-A5-induced 
phosphorylation of EphA4 with an IC50 of 240 
nM and 310 nM. Both cyclic peptides are stable 
in mouse plasma for more than 72 hours and are 
currently the best available EphA4 inhibitors 
(22). Nb 39 and 53 are more potent than the 
KYL-peptide, but similarly potent as APY-d3 
and APY-d4, with KD values in the nanomolar 
range, as measured with SPR. Moreover, both 
Nbs could inhibit EphA4 phosphorylation with 
an IC50 of 170 nM and 261 nM respectively. 
Similar to APY-d3 and APY-d4, Nb 39 and Nb 
53 were stable in mouse serum for more than 72 
hours and maintained their full capability of 
binding EphA4 LBD. The affinity of Nbs could 
still be further increased through error-prone 
PCR mutagenesis and/or making bispecific Nbs 
(40,41). Bivalent or bispecific Nbs can be 
obtained by connecting two identical or different 
Nbs with a linker thereby improving the avidity. 
However, this strategy requires caution in the 
setting of developing EphA4 antagonists, as 
dimerisation of Eph receptors may induce 
clustering and subsequently activation, similar to 
what is obtained with a preclustered antibody 
(42). 
EphA4 has been found to play a role in cancer 
biology and in the pathogenesis of several 
neurological disorders (5). In the central nervous 
system, EphA4 is highly expressed in cell 
bodies, dendritic spines and axons of neurons in 
various brain regions (43,44). EphA4 expression 
is upregulated in axonal stumps after injury (45) 
and in sprouting neurons of aged mice after 
stroke, which contributes to reduced recovery 
(46). Furthermore, blocking EphA4 induced 
more sprouting after spinal cord injury (8). 
EphA4’s negative effect on axonal regeneration 
is mediated through the interaction of the 
receptor with ephrin ligands on surrounding cells 
such as muscle cells, astrocytes, microglia and 
oligodendrocytes (47). Neuronal EphA4 may 
interact with ephrin-A5 and ephrin-B2 of which 
the expression is highly upregulated in reactive 
astrocytes after injury (48-50). This high 
astrocytic ephrin-A5 expression inhibited axonal 
sprouting and motor recovery after stroke (49). 
Also, ephrin-B2 expression decreased axonal 
sprouting as deleting ephrin-B2 from reactive 
astrocytes reduced glial scar formation and 
improved recovery after spinal cord injury and 
this was correlated with an increased 
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regenerative capacity of sprouting spinal cord 
axons (45,48,50). Oligodendrocytes precursor 
cells are glial cells responsible for remyelination 
during neuronal injury or degeneration, thereby 
inhibiting axonal outgrowth (51). Neuronal 
EphA4 may interact with ephrin-A1, ephrin-A3, 
ephrin-A5, ephrin-B1 and ephrin-B2, which have 
been identified in oligodendrocyte precursor 
cells and in mature oligodendrocytes (52-54). In 
addition, enhanced functional recovery was 
observed in ephrin-B3 KO mice after spinal cord 
injury and blocking ephrin-B3 promotes 
remyelination in vivo in a rat model of 
remyelination (55,56). The relative importance 
of the different surrounding cells and different 
ligands is not yet known. However, as EphA4 is 
a promiscuous receptor, targeting EphA4 by 
blocking the interaction with all ephrin ligands 
might be the most efficient therapeutic strategy 
against neurological diseases.  
Treating neurological disorders by targeting 
EphA4 implies using substances that are able to 
penetrate the Blood Brain Barrier (BBB) in order 
to reach their target. In acute injuries, this barrier 
is impaired. In neurodegenerative diseases such 
as ALS, getting drugs across the BBB remains a 
major challenge, despite of the fact that the BBB 
is abnormal in this disease (57-59). Several 
strategies to get biologics across the BBB have 
been developed, such as transcytosis through 
clathrin vesicles and receptor-mediated 
transcytosis by targeting the Low-Density 
Lipoprotein receptor, the transferrin receptor or 
the insulin receptor (60-65). Interestingly, one 
study showed that Nbs with a high isoelectric 
point can cross the BBB spontaneously (66). 
Nbs also have some drawbacks. Although Nb 39 
and Nb 53 remained stable in mouse plasma for 
more than 72 hours, the small size of Nbs limits 
their half-life to about 1.5 h after in vivo 
administration (67). Due to their small size they 
are rapidly cleared from blood via the kidney 
(27). This low half-life can be overcome by 
linking the Nb to serum albumin, which can 
increase the half-life to 20-30 h in mice (68). In 
humans, this approach extended the half-life of 
Nbs to 19 days (68,69). Another strategy to 
increase the half-life of Nbs is coupling 
polyethylene glycol (PEG) groups to the Nbs 
(70). The addition of PEG groups increases the 
apparent molecular weight above the glomerular 
filtration limit avoiding renal clearance and/or 
evades cellular clearance mechanisms (71).  
In summary, we describe for the first time the 
development of Nbs that target the EphA4 LBD. 
We identified two Nbs that were specific for 
EphA4 with residual EphA7 binding, and with 
KD and IC50 values in the nanomolar range. Both 
Nbs were able to block the interaction of EphA4 
with all ephrin ligands, inhibit EphA4 
phosphorylation, and the growth cone collapse 
mediated by EphA4 activation upon ephrin-B3 
interaction. These Nbs may be useful tools to 
study the role of the EphA4 receptor in 
preclinical cancer or neurodegeneration models. 
Furthermore they may represent a starting point 
for an EphA4-based therapeutic approach using 
Nbs. 
 
EXPERIMENTAL PROCEDURES  
  Expression and purification of the 
EphA4 ligand-binding domain - The EphA4 
LBD (AA 22 – AA 203 (17)) was cloned from 
the EphA4 Human cDNA ORF clone (Origene, 
US) and expressed in the E. coli strain BL21 
codon + pICA2 transformed with the 
pLH36Epha plasmid. Expression was induced by 
isopropyl b-D-1-thiogalactopyranoside under 
control of a pL-promotor developed by the 
Protein Service Facility of VIB. The pLH36 
plasmid was provided with a His6- tag followed 
by a murine caspase-3 site. The murine caspase-
3 site can be used to remove the His6-tag 
attached at the N-terminus of the protein of 
interest during purification. The transformed 
bacteria were grown in Luria Bertani medium 
supplemented with ampicillin (100 µg/mL) and 
kanamycin (50 µg/mL) overnight at 28°C 
inoculation (1/100) in a 20 liter fermenter 
provided with Luria Bertani medium 
supplemented with ampicillin (100 µg/mL) and 
1% glycerol. The initial stirring and airflow was 
200 rpm and 1.5 L/min, respectively. Further, 
this was automatically adapted to keep the pO2 at 
30 %. The temperature was kept at 28°C. The 
cells were grown to an optical density of A600nm = 
1.0, transferred at 20°C, and expression was 
induced by addition of 1 mM isopropyl b-D-1-
thiogalactopyranoside overnight. Cells were then 
harvested and frozen at -20°C. After thawing, the 
cells were resuspended at 3 mL/g in 20 mM 
NaH2PO4 pH 7.5, 500 mM NaCl, 20 mM 
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imidazole and 1 mM phenylmethylsulfonyl 
fluoride. The cytoplasmic fraction was prepared 
by sonication of the cells followed by 
centrifugation at 18,000g for 30 min. All steps 
were conducted at 4°C. The clear supernatant 
was applied to a 74 mL Ni-Sepharose 6 FF 
column (GE Healthcare, Belgium), equilibrated 
with 20 mM NaH2PO4 pH 7.5, 500 mM NaCl, 20 
mM imidazole and 0.1% CHAPS. The column 
was eluted with 20 mM NaH2PO4 pH7.4, 20mM 
NaCl, 400mM imidazole and 0.1% CHAPS after 
an extra wash step with 50 mM imidazole. The 
elution fraction was diluted 1/20 with 20 mM 
Tris pH 8.0 and 0.1% CHAPS and loaded on a 
20-mL Source 15Q column (GE Healthcare, 
Belgium) to remove contaminants. After 
equilibration, the protein of interest was eluted 
by a linear gradient over 20 column volumes of 
NaCl from 0 to 1 M in 20 mM Tris pH 8.0 and 
0.1% CHAPS. To the EphA4-containing 
fractions, activated murine caspase-3 (1/100 % 
m/m murine caspase-3/Epha4) with 10 mM DTT 
was added to remove the His6-tag. After 1 h 
incubation at 37°C, the reaction solution was 
injected on a HiLoad 26/60 Superdex 75 prep 
grade with PBS as running solution for 
formulation and to remove minor contaminants, 
His6-tag and murine caspase-3. The obtained 
fractions were analysed by SDS-PAGE and the 
concentration was determined using the Micro-
BCA assay (ThermoFisher Scientific, Belgium).
  
 
  Construction of a VHH library - Nbs 
targeting the EphA4 LBD were obtained in 
collaboration with the VIB Nanobody Service 
Facility. An alpaca was injected subcutaneously 
on days 0, 7, 14, 21, 28 and 35, each time with 
250 µg of human EphA4 LBD. On day 39 
anticoagulated blood was collected for 
lymphocyte preparation. A VHH library was 
constructed as previously described (72-74) and 
screened for the presence of antigen-specific 
Nbs. In brief, total RNA from peripheral blood 
lymphocytes was used as template for first strand 
cDNA synthesis with oligo(dT) primer. Using 
this cDNA, the VHH encoding sequences were 
amplified by PCR, digested with PstI and NotI, 
and cloned into the PstI and NotI sites of the 
phagemid vector pMECS. A VHH library of 
about 2 × 108 independent transformants was 
obtained.  
 
  Isolation of hEphA4 LBD-specific Nbs - 
To screen for the presence of EphA4-specific 
Nbs, the library was subjected to 4 consecutive 
rounds of panning, performed on solid-phase 
coated EphA4 LBD (concentration: ~200 mg/ml, 
~20 mg/well). The enrichment for antigen-
specific phages after each round of panning was 
assessed by comparing the number of phages 
eluted from antigen-coated wells with the 
number of phages eluted from negative control 
(only-blocked) wells. These experiments 
suggested that the phage population was 
enriched for antigen-specific phages after the 3rd 
and 4th round of panning. In total, 190 individual 
colonies from the 3rd and 4th round (95 from each 
round) were randomly selected and analysed by 
ELISA for the presence of antigen-specific Nbs 
in their periplasmic extracts (ELISA using crude 
periplasmic extracts including soluble Nbs). Of 
190 colonies, 41 colonies (14 and 27 from the 3rd 
and 4th round, respectively) scored positive in 
this assay. The VHH genes of the selected genes 
were sequenced to identify the different Nbs.   
 
  Expression and purification of 
recombinant Nbs - pMECS vectors harbouring 
Nb genes were transformed into WK6 E. coli 
cells and the transformed cells were grown in 
Luria Bertani medium supplemented with 
ampicillin (100 µg/mL) and 0.1 % glucose at 
37°C overnight. Subsequently, the cultures were 
inoculated  1/100 to have 1 liter productions in 
Terrific Broth medium supplemented with 
ampicillin (100 µg/mL) and 0.1 % glucose in 
baffles shake flasks. The temperature was kept at 
37°C. The cells were grown to an optical density 
of A600nm = 1.0, transferred at 28°C, and 
expression was induced by addition of 1 mM 
isopropyl b-D-1-thiogalactopyranoside 
overnight. Cells were then harvested and frozen 
at -20°C. The expressed Nbs were extracted from 
the periplasm by osmotic shock and purified 
using His GraviTrap (GE Healthcare, Belgium) 
in parallel, equilibrated with 20 mM NaH2PO4, 
pH 7.5, 300 mM NaCl, 20 mM imidazole, and 1 
mM PMSF. After loading, the columns were 
washed with 20 column volumes of the same 
buffer. The Nbs were first eluted with 20 mM 
NaH2PO4, pH 7.5, 20 mM NaCl, 50 mm 
imidazole, 1 mM PMSF and then with 400 mM 
imidazole in the same buffer. Finally, the Nbs 
were desalted to PBS on sephadex G25 (GE 
Heathcare, Belgium). The obtained fractions 
were analysed with Coomassie-stained SDS-
polyacrylamide gels. Protein concentration was 
 at JO
H
N
SO
N
 &
 JO
H
N
SO
N
 on M
ay 22, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
	   	   EphA4 inhibiting Nanobodies	  
	  
9	  
	  
measured by the Micro-BCA assay 
(ThermoFisher Scientific, Belgium).  
 
  Western Blot – For immunoprecipitation 
experiments, 1 µg of EphA4 LBD, hEphA4-Fc 
(R&D, UK) and mEphA4-Fc (R&D, UK) were 
boiled for 10 min in reducing sample buffer 
(ThermoFisher Scientific, Belgium), and proteins 
were separated in a 4-12% Bis-Tris SDS-PAGE 
gel (ThermoFisher Scientific, Belgium). After 
SDS-PAGE the gel was transferred to 
Immobilon-P membrane (Merck Millipore, 
Belgium) and subsequently blocked with 10% 
Blotting-grade blocker (Biorad, Belgium) for 1 h 
at room temperature. One µg Nb and mouse anti-
HA antibody 1/1000 (clone 16B12, MMS-101P-
200, lot D13FF01646, Covance, US) were used 
to detect EphA4. To determine Nb stability, 10 
ng of Nbs were denatured with reducing sample 
buffer (ThermoFisher Scientific, Belgium) and 
separated in a 12% Tris-glycine SDS-PAGE gel. 
The gel was transferred to Immobilon-P 
membrane, which was afterwards blocked as 
described above. To detect the Nbs, 1/1000 anti-
HA antibody (clone C29F4, 3724S, lot 8, Cell 
Signaling, US) was used.  
 
  Immunoprecipitation experiments - One 
and a half mg protein G magnetic Dynabeads 
(ThermoFisher Scientific, Belgium) was 
preblocked with 1% BSA for 1 h at room 
temperature, washed four times with PBS and 
incubated with 2.5 µg of recombinant mouse or 
human EphA4 protein (R&D, UK) for 10 min at 
room temperature. After washing four times with 
PBS the beads were incubated with 1 µg Nb 
overnight at 4°C. The beads were washed four 
times with PBS, boiled for 10 min in reducing 
sample buffer (ThermoFisher Scientific, 
Belgium), and proteins were separated in a 4-
12% Bis-Tris SDS-PAGE gel (ThermoFisher 
Scientific, Belgium). After SDS-PAGE the gel 
was transferred to Immobilon-P membrane 
(Merck Millipore, Belgium) and subsequently 
blocked with 10% Blotting-grade blocker 
(Biorad, Belgium) for 1 h at room temperature. 
Mouse N-terminal anti-EphA4 antibody 1/1000 
(EM2801, lot 1, ECM Biosciences, US) and 
mouse anti-HA antibody 1/1000 (clone 16B12, 
MMS-101P-200, lot D13FF01646, Covance, 
US) were used to detect EphA4 and Nb 
respectively. To capture EphA4 with Nb anti-HA 
magnetic Dynabeads (ThermoFisher Scientific, 
Belgium) were used and all following steps were 
performed as described above.  
 
Stability experiments - To determine the 
Nb stability in plasma, Nbs were incubated at 
37°C at a concentration of 10 ng/µl in sodium 
heparin not-filtered C57BL/6 mouse plasma 
(BioreclamationIVT, US). At every time-point 
an alliquot was collected and diluted 1/10 in PBS 
for further Western Blot analysis. As a control, 
Nbs were incubated for the same time and at the 
same concentration at 37°C in PBS. Nb stability 
in all samples was next determined with Western 
Blot as described above. Statistical analysis was 
performed using the two-way ANOVA followed 
by Sidak's multiple comparisons posthoc test as 
indicated in the figure legends. A 95 % 
confidence interval was used and values of P < 
0.05 were considered as statistically significant. 
To determine functional stability of Nbs, 
they were first incubated at 37°C in sodium 
heparin not-filtered C57BL/6 mouse plasma at 
500 nM concentration. At every time-point and 
for a maximum of 72 hours, an alliquot was 
collected and stored for further analysis with 
Alphascreen technology. 
  
  Surface Plasmon Resonance - The 
equilibrium dissociation constant (KD) and the 
association (ka1 and ka2) and dissociation rates (kd 
and kd2) were determined using surface plasmon 
resonance detection on a BIACore T200 (GE 
Healthcare, Belgium). Two approaches were 
used. First, the extracellular N-terminal domain 
of human EphA4 was immobilized directly onto 
a CM5 S series sensor chip (GE Healthcare, 
Belgium) using standard amine coupling. After 
activation of the carboxyl moieties on the matrix 
on the chip surface with a 7-min injection of a 
1:1 mixture of 0.4 M EDC and 0.1 M NHS, the 
N-terminal domain of human EphA4 (50 µg/ml 
in 10 mM acetate, pH 4.5) was immobilized to a 
predefined level of 300 response units (RU). A 
flow channel activated with EDC/NHS and 
immediately afterwards blocked by ethanolamine 
served as reference channel. Throughout the 
analysis 10 mM Hepes, 150 mM NaCl, 3 mM 
EDTA, 0.01 mM Surfactant P-20 pH 7.35 was 
used as running buffer. 20 mM glycine pH 2.5 
was used to regenerate the channels (remove all 
bound proteins). The second approach used the 
anti-human Fc capture kit as described by the 
manufacturer. Briefly, approximately 8000 RU 
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anti-human Fc antibody was captured on the 
surface of the channels using amine coupling as 
described above. In a next step, EphA4-hFc 
(both human and mouse EphA4) (R&D, UK) 
fusion protein (2 µg/ml diluted in running buffer) 
was injected (10 µl/min for 6 min) over the 
channel resulting in the capture of approximately 
500 RU of EphA4-hFc fusion protein on the 
surface of the channel. In this approach, a 
channel with only anti-human Fc antibody 
served as reference. 3M MgCl2 was used as 
regeneration buffer. The Nbs were diluted to the 
indicated concentrations in running buffer and 
injected (60 µl/min) over the channel with 
immobilized EphA4 and the reference channel. 
After correction of the response using the 
responses from the reference channel and a blank 
injection of running buffer over the Eph4A-
immobilized channel (double referencing), 
kinetic parameters were determined using 
Biacore T200 evaluation software (GE 
Healthcare, Belgium). Interactions of Nbs with 
different EphA4 recombinant proteins were 
calculated with a 1:1 binding model or a two-
state model. The latter model was used to 
calculate all Nb interactions with EphA4 LBD 
and interactions of Nb 34, 31 and 50 with human 
and mouse EphA4.   
  
  AlphaScreen - To test the specificity of 
the Nbs for the different Eph receptors all Nbs 
were biotinylated with a five times molar excess 
of EZ link NHS biotin (ThermoFisher Scientific, 
Belgium). The Nbs were incubated with the 
biotin for two hours on ice allowing the 
interaction of the biotin with the primary amines 
on the surface of the protein. To remove 
unbound biotin, dialysis was performed with 
PBS in the Slide-A-Lyzer mini dialysis device 
(10 kDa cutoff, ThermoFisher Scientific, 
Belgium). Ten microliter of biotinylated Nbs 
(100 nM) were incubated with 10 µl of a 
subhooking concentration of mouse recombinant 
Eph receptor (Fc-tagged; R&D, UK) for one 
hour in standard buffer (50 mM Hepes, 100 mM 
NaCl, 0.1% Triton and 0.1% BSA) in white 
opaque 384-well microplates (Perkin Elmer, 
Belgium) to avoid the hooking effect 
(oversaturation of donor and acceptor beads 
inhibiting their association). The determined 
subhooking concentrations were 10 nM for 
EphA2, A3, A4, A6, B2 and B6, 30 nM for 
EphA7 and B3, B4 and 100 nM for EphA8. 
Subsequently we incubated first one hour with 
10 µl of anti-IgG AlphaLISA acceptor beads (20 
µg/ml, Perkin Elmer, Belgium) and then 
incubated an additional 30 minutes with 10 µl 
streptavidin donor beads (20 µg/ml, Perkin 
Elmer, Belgium). Incubation steps were 
performed at room temperature and protected 
from light.  
  To test the inhibition of interaction 
between EphA4 and its different ligands, the 
EphA4 LBD (2 mg/ml) was biotinylated with a 
two and a half times molar excess of EZ link 
NHS biotin (ThermoFisher Scientific, Belgium) 
for two hours on ice allowing the interaction of 
the biotin with primary amines on the surface of 
the protein. To remove unbound biotin, dialysis 
was performed with PBS in the Slide-A-Lyzer 
mini dialysis device (10 kDa cutoff, 
ThermoFisher Scientific, Belgium). Five 
microliter of a subhooking concentration of 
biotinylated EphA4 LBD (10 nM) was incubated 
with 5 µl of different concentrations of Nb for 
one hour in standard buffer (50 mM Hepes, 100 
mM NaCl, 0.1% Triton and 0.1% BSA). 
Subsequently, 5 µl of subhooking concentration 
of recombinant ephrin ligand (Fc-tagged; R&D, 
UK) was added and incubated for one hour at 
room temperature. The determined subhooking 
concentrations were 3 nM for ephrin-A1 and 
ephrin-A4, and 10 nM for ephrin-A2/3, ephrin-
A5 and ephrin-B1-3. Next, 5 µl of anti-IgG 
AlphaLISA acceptor beads (20 µg/ml; Perkin 
Elmer, Belgium) and five microliter streptavidin 
donor beads (10 µg/ml; Perkin Elmer, Belgium) 
were added and incubated for one hour and 30 
minutes respectively at room temperature, 
protected from light. A Nb targeting SOD1 was 
used as negative control in all Eph binding 
assays. 
To test the inhibition of EphA7 and 
ephrin-A5 interaction, His-tagged human ephrin-
A5 (Sino Biological, China) was biotinylated 
with a five times molar excess of EZ link NHS 
biotin (ThermoFisher Scientific, Belgium), as it 
is described for the Nbs. Briefly, ephrin-A5 was 
incubated with the biotin for two hours on ice, 
and dyalysed in PBS with the Slide-A-Lyzer 
mini dialysis device (10 kDa cutoff, 
ThermoFisher Scientific, Belgium), to remove 
unbound biotin. microliter of a subhooking 
concentration of human EphA7 (3 nM) was 
incubated with 5 µl of different concentrations of 
Nb for one hour in standard buffer (50 mM 
Hepes, 100 mM NaCl, 0.1% Triton and 0.1% 
BSA). Next, 5 µl of subhooking concentration of 
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biotinylated ephrin-A5 ligand (30 nM) was 
added and incubated for one hour at room 
temperature. Finally, 5 µl of anti-IgG 
AlphaLISA acceptor beads (20 µg/ml; Perkin 
Elmer, Belgium) and 5 µl streptavidin donor 
beads (20 µg/ml; Perkin Elmer, Belgium) were 
added and incubated for one hour and 30 minutes 
respectively at room temperature, protected from 
light. A control Nb targeting chicken lysozyme 
was used as negative control, and untagged 
ephrin-A5 was used as positive control. 
In order to determine the capability of 
Nbs to bind EphA4 after plasma incubation, 500 
nM Nbs pre-incubated in plasma were first 
diluted in PBS at the time of the Alphascreen 
assay, to reach a final subhooking Nb 
concentration of 10 nM. Five microliter of a 
subhooking concentration of biotinylated EphA4 
LBD (10 nM) was incubated with 5 µl of 10 nM 
Nb 39 and Nb 53 for one hour in standard buffer 
(50 mM Hepes, 100 mM NaCl, 0.1% Triton and 
0.1% BSA). Next, 5 µl of anti-HA AlphaLISA 
acceptor beads (20 µg/ml; Perkin Elmer, 
Belgium) and five microliter streptavidin donor 
beads (10 µg/ml; Perkin Elmer, Belgium) were 
added and incubated for one hour and 30 minutes 
respectively at room temperature, protected from 
light. As a control to assess the specificity of the 
binding, 300 nM of ephrin-B2 ligand ((Fc-
tagged; R&D, UK) was incubated with EphA4 
LBD for one hour prior to the addition of the 
Nbs.  
Plates were read on the Envision 
Multilabel Reader (Perkin Elmer, Belgium). 
 
 Phosphorylation assay - The amount of 
phosphorylation of EphA4 was determined using 
the PathHunter assay (DiscoveRx Corporation, 
UK) with U2OS cells adapted for the EphA4 
receptor according to manufacturer’s 
instructions. In short, a small peptide epitope is 
expressed recombinantly on the intracellular C-
terminus of the EphA4 receptor tyrosine kinase. 
An interaction partner containing SH2 domains 
is co-expressed with a larger sequence, termed 
enzyme activator (EA). Activation with 
recombinant human ephrin-A1-Fc causes EphA4 
receptor dimerisation, leading to cross-
phosphorylation of tyrosine residues on the 
cytoplasmic domain of the receptor. The SH2-
EA fusion protein binds the phosphorylated 
receptor enabling the complementation of EA 
and the peptide epitope, yielding an active β-
galactisodase enzyme. This interaction can be 
visualised with a chemiluminescent substrate. 
Increasing concentrations of the Nbs were added 
to the medium before ephrin-A1-Fc stimulation. 
20 µl of  5000 EphA4-expressing U2OS cells 
were plated in 384-well plates and incubated for 
24 h at 37°C 5% CO2. Five µl Nb dilutions or 
vehicle were added per well followed by 
incubation for 1 h at 37°C. Five µl of ephrin-A1-
Fc (1.2 µg/ml) or vehicle were added to each 
well followed by incubation for 3 h at room 
temperature. Twelve µl of detection reagent 
(Galacton Star, Emerald II solution, PathHunter 
cell assay buffer in relative volumes of 1:5:19 
respectively) was added, incubated for 1 h at 
room temperature and read on a Pherastar (BMG 
Labtech, Germany). Percentage activity was 
calculated as (signal - non-stimulated control (no 
ephrin added)) / (ephrin stimulated condition - 
non-stimulated control)) * 100. Positive and 
negative controls were Dasatinib and a Nb 
targeting Superoxide Dismutase 1 (SOD1) 
respectively. 
Growth cone collapse - The cortex of 
7.5-day-old mice was dissociated by 
trypsinisation and trituration. Cortical neurons 
were cultured on 13 mm-diameter cover-slips 
coated with poly-L-Lysine, at a density of 15000 
cells/cover-slip, in MEM medium with Earle’s 
salt and L-glutamine and supplemented with 
10% heat-inactivated horse serum and penicillin 
and streptomycin (ThermoFisher Scientific, 
Belgium). Cultures were kept in a 5% CO2 
humidified incubator at 37°C. Medium was 
replaced for Neurobasal medium supplemented 
with B27, 500 µM L-glutamine and penicillin 
and streptomycin (ThermoFisher Scientific), 4 
hours after plating. 24 hours after plating the 
cultures were incubated for 30 min with KYL 
peptide at a concentration of 1 µM or 30 µM, or 
Nb 53 or Nb 39 at a concentration of 1 µM. 
Cultures were next stimulated with 1 µg/ml 
mouse pre-clustered ephrin-B3-Fc, or Fc (R&D, 
UK) as a control, for 30 min in the presence of 
the KYL peptide or the Nbs. Cortical neurons 
were fixed for 20 min in 4% paraformaldehyde 
(ThermoFisher Scientific, Belgium), 
permeabilized in 0.2% Triton X-100 in PBS and 
stained with Alexa Fluor 555-conjugated 
phalloidin (ThermoFisher Scientific, Belgium). 
Growth cone collpase was scored for each 
condition under a Zeiss Axioimager M1 
epifluorescence and brightfield upright 
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microscope with a Zeiss A-Plan 40X/0.65 ∞/0.17 
objective (Carl Zeiss, Germany). Growth cone 
collapse was considered when no lamellipodia or 
filopodia were present at the tip of the longest 
neurite of every scored neuron. Growth cone 
collapse was scored in a blinded manner for 40-
160 neurons in every condition and experiment. 
Images were obtained with Axiocam MRm 
monochrome digital camera and Zeiss 
AxioVision V 4.8.2.0 software (Carl Zeiss, 
Germany) at the same magnification. Statistical 
analysis was performed using the one-way 
ANOVA followed by Tukey’s post hoc test as 
indicated in the figure legends. A 95 % 
confidence interval was used and values of P < 
0.05 were considered as statistically significant. 
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Table 1. Overview of the EphA4-Nanobody binding constants. Association constants (ka1 and ka2), 
dissociation constants (kd1 and kd2) and equilibration constants (KD) were determined by Surface 
Plasmon Resonance (SPR) through kinetics analysis. SPR analyses were performed in duplicate. 
Alternating red and black colour indicates different Nb groups, based on their clonal origin.  
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FIGURE LEGENDS 
 
Figure 1. Amino acid sequence of 15 different anti-EphA4 LBD Nbs. Nbs were numbered 
according to Kabat numbering with reference sequence VH3-23/JH5 (human germline sequence on 
average most closely related to Nanobody sequences) on top. The CDRs were assigned according to 
the AbM definitions and are shown with a grey background. The Nbs belonged to nine clonally-
unrelated B-cell clones and the different groups are shown alternatively in black and purple. 
According to the amino acid sequences Nb 90 and 60; Nb 19 and 57; Nb 34 and 47; Nb 31, 50, 10 and 
53 belonged to the same group. Nb 39, 16, 71, 28 and 22 belonged to unrelated B-cell clones. 
Figure 2. Nbs bind native EphA4 LBD. Nbs and EphA4 co-immunoprecipitated together, both when 
immunoprecipitating different Nbs (left panel) or when immunoprecipitating EphA4 (right panel). (A, 
B) Nb 53 and Nb 39 could capture EphA4 and could be captured by EphA4. (C) Nb 22 showed lower 
affinity for mouse EphA4 compared to human EphA4. (D, E) Nb 19 and 47 showed unspecific binding 
to the beads. (F) Nb 60 showed cross-reactivity with ephrin-B2, which was performed as a negative 
control experiment.  
Figure 3. Selectivity for EphA4 and cross-reactivity with other Eph receptors. Using AlphaScreen 
technology we determined the selectivity of the Nbs for EphA4 receptor and the cross-reactivity with 
other Eph receptors. (A) Next to EphA4, Nb 60 also interacted with many other different Eph 
receptors. (B-F) Nb 57, 22, 39, 31 and 53 presented the highest selectivity to the EphA4 receptor. (F) 
Nb 50 had the lowest selectivity for EphA4 as it also interacted with EphA3, EphA6, EphA7 and 
EphA8. All assays were done in duplicate and data are represented as mean ± SD. 
Figure 4. Nbs compete with ephrin ligands in binding EphA4. With AlphaScreen technology we 
determined the capability of the Nbs in inhibiting the binding to EphA4 LBD. (A, D, E, H) Nb 22 and 
31 could not completely inhibit ephrin-ligand binding to EphA4 LBD, whereas Nb 39 and Nb 53 
succeeded in doing so even at a lower concentration than the KYL-peptide, which was used as a 
positive control. (B, F, G) Nb 22 did not show complete inhibition Nb 39, Nb 53 and Nb 31 showed 
complete inhibition of ligand-binding at a lower concentration than the KYL-peptide. (C) Nb 39 and 
53 showed complete inhibition of ligand-binding at a lower concentration than Nb 22, Nb 31 and the 
KYL-peptide. Trendlines are only shown when complete inhibition was reached. All assays were done 
in duplicate and data are represented as mean ± SD. 
Figure 5. Nb 39 and Nb 53 do not completely inhibit ephrin-A5 binding to EphA7. With 
alphascreen technology we determined whether Nb 39 and Nb 53 could inhibit ephrin-A5 binding to 
EphA7. These Nbs did not completely inhibit the interaction between ephrin-A5 and EphA7 at the 
highest concentrations tested. This assay was done in triplicate and data are represented as mean ± SD. 
Figure 6. Nbs inhibit ephrin-induced EphA4 phosphorylation. With the PathHunter assay we could 
determine that Nb 39 and Nb 53 completely inhibited EphA4 phosphorylation triggered by ephrin-A1 
binding, even at a lower concentration than the KYL-peptide. All assays were performed in triplicate 
and data are represented as mean ± SD. 
Figure 7. Nbs inhibit ephrin-B3-EphA4 mediated growth cone collapse. Nb 53 and Nb 39 (1 µM) 
reversed ephrin-B3-mediated growth cone collapse. (A) E17.5 cortical neurons were first treated at 
24h after culture with 1 µM or 30 µM KYL peptide or 1 µM Nb for 30 min, and then stimulated with 1 
µg/ml preclustured ephrin-B3-Fc or Fc as a control for 30 min in the presence of the Nb. A control 
condition without any kind of treatment was also scored (Control). Cells were stained with Alexa 
Fluor 555-conjugated phalloidin and DAPI. Growth cone collapse was determined for every neuron by 
analysing the tip of only the longest neurite (white arrowheads). Scale bar, 10 µm. (B) Percentage of 
growth cone collapse was determined in every experimental condition by assessing 40-160 neurons 
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under a Zeiss fluorescence microscope. Percentage of collapse is expressed as the mean of collapse of 
6 independent experiments ± SD, and was compared between different conditions by one-way 
ANOVA followed by Tukey's multiple comparisons posthoc test. ** p<0.01 and *** p<0.0001, as 
compared with control and Fc conditions. # p<0.05, as compared with the ephrin-B3 condition. 
Figure 8. Nbs are stable in plasma for at least 72 hours. Nbs were incubated in heparinized mouse 
plasma at 37°C until a maximum of 168 hours. Western Blot against HA tag was performed to detect 
Nb 39 and Nb 53 full-length and cleavage products (A). Quantifications of full-length Nb band (B) 
were referred to the full-length band at 0h for each Nb respectively. Means of 3-5 independent 
experiments ± SD are represented. Time factor was analysed by two-way ANOVA followed by 
Sidak's multiple comparisons posthoc test. * p<0.05 and *** p<0.0001, as compared with 0 h time-
point. Differences between the two Nbs were determined by two-way ANOVA, but not identified 
(n.s.). Nb incubation in PBS did not give rise to degradation products as detected by Western Blot (C). 
Incubation of Nbs in plasma at 37°C until a maximum of 72 hours did not affect the capability of those 
in binding EphA4 LBD (D). All values represent the percentage of Nb-EphA4 LBD binding respect to 
the 0 h time-point. This assay was done in triplicate and data are represented as mean ± SD. 
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Figure 1.  
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Figure 2.  
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Figure 3.  
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Figure 4.  
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Figure 5. 
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Figure 6.  
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Figure 7.  
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Figure 8.  
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